B Nosyk1, B D L Marshall, B Fischer, J S G Montaner, E Wood, T Kerr. 1. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, University of British Columbia, 608-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. bnosyk@cfenet.ubc.ca
Abstract
BACKGROUND: The nonmedical use of prescribed opioids (POs) has increased across North America over the past decade. Our objective was to identify changes in the availability of POs and other illicit drugs among drug users in a Canadian setting. METHODS: Information on the availability of illicit drugs was collected in standardized interviews from a large observational research program involving illicit drug users in Vancouver, British Columbia from 2006 to 2010. The primary outcome was the perceived availability of a set of six POs (aspirin/oxycodone, hydromorphone, oxycodone, morphine, acetaminophen/codeine and methadone) among individuals reporting ever using POs. Availability was measured in three levels: not available, delayed availability (available ≥10 min), and immediate availability (available <10 min). Multivariate ordinal logistic regression models were executed to estimate the trend in PO availability, controlling for individual characteristics hypothesized to influence availability. RESULTS: 1871 individuals were followed during the study period (2006-2010), including 583 (31.2%) women. The availability of POs increased over time, regardless of changes in the characteristics of cohort entrants. These increases were observed while the availability of traditional drugs of abuse (e.g., heroin and cocaine) remained constant. The adjusted odds of delayed availability vs. unavailability were between 34% (hydromorphone) and 71% (acetaminophen/codeine) greater in each calendar year. DISCUSSION: The availability of POs among drug users in a Canadian setting increased markedly over a relatively short timeframe, despite persistent and high availability of heroin and cocaine. Further study is required to determine the context of use of POs, associated harms, as well as policy responses to increasing availability.
BACKGROUND: The nonmedical use of prescribed opioids (POs) has increased across North America over the past decade. Our objective was to identify changes in the availability of POs and other illicit drugs among drug users in a Canadian setting. METHODS: Information on the availability of illicit drugs was collected in standardized interviews from a large observational research program involving illicit drug users in Vancouver, British Columbia from 2006 to 2010. The primary outcome was the perceived availability of a set of six POs (aspirin/oxycodone, hydromorphone, oxycodone, morphine, acetaminophen/codeine and methadone) among individuals reporting ever using POs. Availability was measured in three levels: not available, delayed availability (available ≥10 min), and immediate availability (available <10 min). Multivariate ordinal logistic regression models were executed to estimate the trend in PO availability, controlling for individual characteristics hypothesized to influence availability. RESULTS: 1871 individuals were followed during the study period (2006-2010), including 583 (31.2%) women. The availability of POs increased over time, regardless of changes in the characteristics of cohort entrants. These increases were observed while the availability of traditional drugs of abuse (e.g., heroin and cocaine) remained constant. The adjusted odds of delayed availability vs. unavailability were between 34% (hydromorphone) and 71% (acetaminophen/codeine) greater in each calendar year. DISCUSSION: The availability of POs among drug users in a Canadian setting increased markedly over a relatively short timeframe, despite persistent and high availability of heroin and cocaine. Further study is required to determine the context of use of POs, associated harms, as well as policy responses to increasing availability.
Authors: Paul Kurdyak; Tara Gomes; Zhan Yao; Muhammad M Mamdani; Chelsea Hellings; Benedikt Fischer; Jürgen Rehm; Ahmed M Bayoumi; David N Juurlink Journal: Addiction Date: 2012-01-18 Impact factor: 6.526
Authors: Andrew Rosenblum; Mark Parrino; Sidney H Schnoll; Chunki Fong; Carleen Maxwell; Charles M Cleland; Stephen Magura; J David Haddox Journal: Drug Alcohol Depend Date: 2007-03-26 Impact factor: 4.492
Authors: Kenneth A Harris; Julia H Arnsten; Herman Joseph; Joe Hecht; Ira Marion; Patti Juliana; Marc N Gourevitch Journal: J Subst Abuse Treat Date: 2006-09-07
Authors: Evan Wood; Mark W Tyndall; Patricia M Spittal; Kathy Li; Aslam H Anis; Robert S Hogg; Julio S G Montaner; Michael V O'Shaughnessy; Martin T Schechter Journal: CMAJ Date: 2003-01-21 Impact factor: 8.262
Authors: Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski Journal: J Pain Date: 2009-02 Impact factor: 5.820
Authors: Ryan McNeil; Thomas Kerr; Solanna Anderson; Lisa Maher; Chereece Keewatin; M J Milloy; Evan Wood; Will Small Journal: Soc Sci Med Date: 2015-04-07 Impact factor: 4.634
Authors: Anees Bahji; Evan Wood; Keith Ahamad; Huiru Dong; Kora DeBeck; M-J Milloy; Thomas Kerr; Kanna Hayashi Journal: Int J Drug Policy Date: 2015-09-30
Authors: Ricky N Bluthenthal; Lynn Wenger; Daniel Chu; Jennifer Lorvick; Brendan Quinn; James P Thing; Alex H Kral Journal: Drug Alcohol Depend Date: 2015-02-19 Impact factor: 4.492
Authors: Stephanie Lake; Evan Wood; Jane Buxton; Huiru Dong; Julio Montaner; Thomas Kerr Journal: Am J Drug Alcohol Abuse Date: 2015-02-20 Impact factor: 3.829